CompletedNCT00119756

A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With Schizophrenia

This study evaluated the safety of paliperidone palmitate for people with schizophrenia.

Medication studyAges 18+

The study in practice

Understand this study

This study evaluated the safety of paliperidone palmitate for people with schizophrenia.

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Study clarity

Study start dateJune 2005

Recruitment status: Completed
Enrollment listed in the registry: 253
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Not clearly listed
Age range: Over 18 Years
Official registry ID: NCT00119756
Official title: Show the full official title
A Randomized, Crossover Study to Evaluate the Overall Safety and Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Patients With Schizophrenia

Completed

Locations not listed

FAQ

What did researchers investigate?

This study evaluated the safety of paliperidone palmitate for people with schizophrenia.

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including paliperidone palmitate.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.